Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Healthcare
Biotechnology
15.50 $
-1.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -55 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| -26 | -20 | 19 | -33 | -55 | |
| 0.3 | 0.3 | 0.2 | 0.3 | 0.3 | |
| 1.7 | 1.9 | 2.2 | 6.8 | 10 | |
| 0.1 | -1.3 | -1.0 | 5.3 | -6.0 | |
| 0.2 | 0.1 | 0.4 | 0.5 | 0.2 | |
| -65 | 22 | -66 | -70 | -3.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | – | |
| 0.0 | -1.3 | -3.8 | 0.0 | – | |
| 80 | -1.2 | 56 | 109 | 113 | |
| -11 | 0.9 | 10.0 | 6.4 | 54 | |
| -26 | -20 | 19 | -33 | -56 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.